BioStem Technologies, Inc. to Post Q1 2024 Earnings of $0.74 Per Share, Zacks Small Cap Forecasts (OTCMKTS:BSEM)

BioStem Technologies, Inc. (OTCMKTS:BSEM) – Investment analysts at Zacks Small Cap increased their Q1 2024 EPS estimates for shares of BioStem Technologies in a research note issued on Tuesday, April 2nd. Zacks Small Cap analyst B. Sorensen now anticipates that the company will post earnings per share of $0.74 for the quarter, up from their previous forecast of $0.65. The consensus estimate for BioStem Technologies’ current full-year earnings is $2.64 per share. Zacks Small Cap also issued estimates for BioStem Technologies’ Q2 2024 earnings at $0.77 EPS, Q3 2024 earnings at $0.80 EPS, Q4 2024 earnings at $0.83 EPS, Q1 2025 earnings at $0.79 EPS, Q2 2025 earnings at $0.80 EPS, Q3 2025 earnings at $0.80 EPS and Q4 2025 earnings at $0.81 EPS.

BioStem Technologies (OTCMKTS:BSEM) last posted its quarterly earnings results on Monday, April 1st. The company reported -0.14 earnings per share (EPS) for the quarter. The firm had revenue of 11.44 million for the quarter, compared to the consensus estimate of 11.40 million.

BioStem Technologies Stock Performance

Shares of OTCMKTS:BSEM opened at 14.10 on Thursday. The firm has a 50-day moving average price of 9.11. BioStem Technologies has a fifty-two week low of 1.20 and a fifty-two week high of 15.50.

About BioStem Technologies

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.